Specialty Pharma Journal Specialty, Precision & Technology
ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low …
Tag Archives: Parkinson’s disease
December, 2018
November, 2018
-
15 November
Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
CAMBRIDGE, England and NORTH CHICAGO, Ill.–(BUSINESS WIRE)–Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global biopharmaceutical company, today announced a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease …
November, 2017
-
20 November
Acorda Discontinues Development of its Late-Stage Parkinson’s Disease Drug due to Safety Concerns
ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it is discontinuing its clinical development program for tozadenant, an investigational treatment for Parkinson’s disease, including immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies. The Company made this decision based on new information obtained from the Phase …
-
15 November
Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths
ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc.(Nasdaq:ACOR) today announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease. The Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated …
August, 2017
-
25 August
FDA Approves Adamas’ Gocovri for the Treatment of Dyskinesia in Parkinson’s Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI, previously granted orphan drug status by …
April, 2017
-
7 April
FDA Approves 23andMe’s At-Home DNA Test to Predict Risk for 10 Diseases
The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or conditions, which …
March, 2017
-
22 March
FDA Approves Newron’s Xadago for Treatment of Patients with Parkinson’s Disease
Milan, Italy and Morristown, NJ, U.S.A., – March 21, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced today …
February, 2017
-
13 February
Acorda Therapeutics’ Inhaled Drug Successfully Reduces Parkinson’s Disease Symptoms in Late-Stage Study
ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods …
December, 2016
-
16 December
Celgene and Evotec Partner for Development of Drugs for Neurodegenerative Diseases
HAMBURG, Germany–(BUSINESS WIRE)–* Exclusive broad R&D collaboration based on Evotec’s unique induced pluripotent stem cell (“iPSC”) platform which enables systematic drug screening in patient-derived disease models Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and …
May, 2016
-
4 May
Biogen to Spin Off Hemophilia Business into Separate Company
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (NASDAQ: BIIB) today announced that it intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise. “We …